Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner

BACKGROUND: The dipeptidyl peptidase-4 (DPP-4) inhibitors Sitagliptin and Vildagliptin lower blood glucose by augmenting endogenous levels of glucagon-like peptide-1 (GLP-1), an incretin which also confers cardioprotection. As such, we hypothesized that treatment with DPP-4 inhibitors are also cardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hausenloy, Derek J, Whittington, Hannah J, Wynne, Abigail M, Begum, Shah S, Theodorou, Louise, Riksen, Niels, Mocanu, Mihaela M, Yellon, Derek M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815626/
https://www.ncbi.nlm.nih.gov/pubmed/24148218
http://dx.doi.org/10.1186/1475-2840-12-154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815626/
https://www.ncbi.nlm.nih.gov/pubmed/24148218
http://dx.doi.org/10.1186/1475-2840-12-154

Ejemplares similares